4.24

1.44% 0.06

After Hours: 4.31 0.07 +1.65%

Aquestive Therapeutics Inc (AQST)

Overview News Price History Option Chain Financials Discussions Forecast

Aquestive Therapeutics Inc stock is traded at $4.24, with a volume of 1.45M. It is up +1.44% in the last 24 hours and up +7.89% over the past month. Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

Previous Close:

$4.18

Open:

$4.19

24h Volume:

1.45M

Relative Volume:

0.85

Market Cap:

$531.98M

Revenue:

$50.27M

Net Income/Loss:

$-68.91M

P/E Ratio:

-7.0315

EPS:

-0.603

Net Cash Flow:

$-44.32M

1W Performance:

+1.92%

1M Performance:

+7.89%

6M Performance:

-32.05%

1Y Performance:

+13.98%

1-Day Range:

$4.175

$4.29

1-Week Range:

$4.135

$4.355

52-Week Range:

$2.93

$7.55

Aquestive Therapeutics Inc Stock (AQST) Company Profile

Name

Aquestive Therapeutics Inc

Sector

Healthcare (1100)

Industry

Drug Manufacturers - Specialty & Generic (86)

Phone

908-941-1900

Address

30 TECHNOLOGY DRIVE, WARREN, NJ

Employee

147

Twitter

Next Earnings Date

2026-08-10

Latest SEC Filings

AQST's Discussions on Twitter

Compare AQST vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AQST Aquestive Therapeutics Inc	4.24	521.94M	50.27M	-68.91M	-44.32M	-0.603
TAK Takeda Pharmaceutical Co Adr	16.89	50.65B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.72	41.09B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	35.29	39.45B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	75.42	30.13B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	547.25	23.00B	3.17B	1.29B	1.01B	27.09

Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-24-26	Resumed	Oppenheimer	Outperform
Jun-02-25	Resumed	Oppenheimer	Outperform
Dec-17-24	Initiated	Cantor Fitzgerald	Overweight
May-10-24	Initiated	Leerink Partners	Outperform
Apr-11-24	Initiated	Piper Sandler	Overweight
Mar-28-24	Initiated	Raymond James	Outperform
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Apr-22-19	Initiated	H.C. Wainwright	Buy
Jan-03-19	Initiated	Lake Street	Buy
Aug-20-18	Initiated	JMP Securities	Mkt Outperform
Aug-20-18	Initiated	RBC Capital Mkts	Outperform

View All

Aquestive Therapeutics Inc Stock (AQST) Latest News

Jun 30, 2026

AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review

Jun 30, 2026

Jun 28, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire

Jun 28, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review

Jun 28, 2026

Jun 26, 2026

SEC Form S-3 filed by Aquestive Therapeutics Inc. - Quantisnow

Jun 26, 2026

Form S-3 Aquestive Therapeutics Inc For: 26 June By Investing.com - Investing.com India

Jun 26, 2026

LifeSci Capital Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9 - Moomoo

Jun 25, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Investors to Inquire about Securities Investigation - ACCESS Newswire

Jun 25, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeut - The National Law Review

Jun 25, 2026